Stereotactic body radiotherapy delays the need for long-term androgen deprivation therapy (ADT) in many men with oligometastatic prostate cancer, a study shows.

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...

Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumor’s growth.

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

ADT reduces testosterone, crucial for prostate cancer cell growth, but causes side effects impacting quality of life. Cardiovascular risks, insulin resistance, and bone density loss are significant ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is ...

If you’ve been diagnosed with advanced prostate cancer, there’s a good chance you’ll receive androgen deprivation therapy (ADT) at some point, as ADT is a mainstay of prostate cancer treatment. It ...